Compare Adaptive Biotechnologies Corp (ADPT) vs Air Products & Chemicals, Inc. (APD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Air Products & Chemicals, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Air Products & Chemicals, Inc. trades at $297.37 (market cap $67.93B). The key difference: Air Products & Chemicals, Inc. is far larger — about 20.4× Adaptive Biotechnologies Corp's market cap, and Air Products & Chemicals, Inc. pays a 2.37% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | APD | |
|---|---|---|
Market Cap | $3.33B | $67.93B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $314.19 |
52-Week Low | $10.24 | $230.42 |
Enterprise Value | $3.19B | $85.34B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
APD trades at $305.05, down 2.91% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, though 2025 saw a net loss of $394.50 million. Recent strategic moves include exiting the Louisiana Clean Energy Complex and finalizing a renewable ammonia deal with Yara, signaling a refined growth focus.
The outlook is positive with a consensus price target of $324.89, implying 6.5% upside. Risks include high debt levels and volatile cash flows from heavy investments. Investors should weigh the company's long-term growth projects against near-term financial pressures and geopolitical uncertainties affecting supply chains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →
